The reviewers stated they found “a trend which suggests the possibility of bias from compensation” when payments or stock holdings were analyzed in an FDA review process to determine whether Dynesys, now used for spinal fusion, could also be used for patients with pain from back injuries.
However, the reviewers added that Dynesys was at least as effective as another Zimmer product, the Silhouette Spinal Fixation System, in treating patients with the new indication.
Read the FDA report on Zimmer’s Dynesys Spinal System (pdf).
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
